Nova Immunotherapeutics Limited Report issue

For profit Phase 1
Founded: Wigston United Kingdom (2014)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2015
NCT02500680
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Nova Immunotherapeutics Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 1 (Phase 1)

Influenza, Human (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 3